Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 8/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370471 | 0.91 | RAD51 (0.73) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25429800 | 0.90 | RAD51 (0.65) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25433271 | 0.90 | RAD51 (0.65) | RAD51ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL25434254 | 0.90 | RAD51 (0.76) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL23498259 | 0.89 | RAD51 (1.00) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL30590401 | 0.89 | RAD51 (0.64) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25431688 | 0.89 | RAD51 (0.64) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25432853 | 0.88 | RAD51 (0.69) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL30590352 | 0.88 | RAD51 (0.69) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL23497986 | 0.87 | RAD51 (0.81) | RAD51ALDH1A1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | claimed |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | RAD51 1/4885ALDH1A1 4307/4885KDM4E 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.